BPC-157: Benefits, Dosage & FDA Status
Body Protection Compound-157
A 15-amino-acid peptide derived from gastric juice. The most popular recovery peptide with 100+ preclinical studies showing accelerated healing of tendons, ligaments, muscle, gut lining, and nerves.
FDA Status
Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026)
Typical Dose
250–500 mcg twice daily (subcutaneous)
Evidence Grade
B+Multiple clinical studies + widespread clinical use
Half-Life
~4 hours (subcutaneous)
Routes of Administration
subcutaneous, oral, intramuscular
First Synthesized
1991
Clinics Indexed
308 providers have offered BPC-157 in our tracked directory.
Mechanism of Action
Upregulates VEGF and growth-factor signaling, accelerates angiogenesis, modulates nitric oxide and dopaminergic pathways involved in wound healing.
Key Reported Benefits
- ✓Tendon & ligament repair
- ✓Gut healing
- ✓Muscle recovery
- ✓Neuroprotection
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B+ indicates multiple clinical studies + widespread clinical use.
Reported Side Effects
- •Injection-site irritation
- •Mild fatigue (rare)
- •Dizziness (rare)
Contraindications
- ⚠Active malignancy (theoretical concern with VEGF upregulation)
- ⚠Pregnancy / breastfeeding
Commonly Stacked With
TB-500
A synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
GHK-Cu
A naturally occurring copper-binding tripeptide that modulates 4,000+ human genes. The most studied peptide for skin rejuvenation with both preclinical and clinical topical evidence.
Regulatory & Safety Context
FDA status: Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026)
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on BPC-157. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
TB-500
BA synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
CJC-1295 (no DAC)
BA growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
Hexarelin
BThe strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.
KPV
C+The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
Larazotide
B+An 8-amino-acid oral peptide that tightens intestinal tight junctions by antagonizing zonulin signaling. The most-studied 'leaky gut' peptide with celiac trial data.
PDA
C+A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.